Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUNAVAIL vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
FDA-approved for the treatment of opioid dependence, including induction and maintenance therapy.
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Terminal elimination half-life of buprenorphine is approximately 24-42 hours (mean ~37 hours) due to slow dissociation from mu-opioid receptors, supporting extended dosing intervals.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Buprenorphine is primarily metabolized via N-dealkylation by CYP3A4 to norbuprenorphine; also undergoes glucuronidation. Naloxone undergoes hepatic metabolism primarily by glucuronidation.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Fecal (~70%) as unconjugated buprenorphine and metabolites; renal (~30%) primarily as conjugated metabolites.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Approximately 96% bound to alpha- and beta-globulins, not significantly to albumin.
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
Vd: 2.5-4.0 L/kg, indicating extensive tissue distribution and high lipophilicity.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Buccal: ~30-40% relative to intravenous; sublingual: ~30% due to first-pass metabolism; buccal route avoids some gastrointestinal degradation.
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl < 30 m L/min): use with caution; consider dose reduction or extended intervals due to potential accumulation of buprenorphine.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B): reduce starting dose by 50% and titrate slowly. For mild impairment (Child-Pugh class A): no dose adjustment required.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Not approved for patients under 16 years; safety and efficacy not established. For adolescents 16 years and older: use adult dosing based on weight and severity.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
No specific dose adjustment in elderly; use caution due to increased sensitivity, impaired hepatic/renal function, and risk of falls. Start at low end of dosing range and titrate slowly.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
Risk of addiction, abuse, and misuse; respiratory depression and death with IV administration; neonatal opioid withdrawal syndrome with prolonged use; risk of opioid withdrawal with abrupt discontinuation; risk of hepatitis, hepatic events; precipitation of withdrawal if given to patients dependent on full agonists.
None
Respiratory depression; neonatal opioid withdrawal syndrome; hepatic injury; precipitation of opioid withdrawal; risks from concomitant use with benzodiazepines or CNS depressants; dependence and withdrawal; use in patients with compromised respiratory function; increased intracranial pressure; hypotension; biliary tract disease; QT prolongation; impairment of driving/operating machinery.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Hypersensitivity to buprenorphine or naloxone; patients with significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; patients not already dependent on opioids (for induction).
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
No significant food interactions. However, patients should avoid grapefruit juice as it may increase buprenorphine levels. Advise to take on an empty stomach for consistent absorption, though food does not significantly alter bioavailability.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Use in pregnancy only if benefit outweighs risk.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Buprenorphine is excreted into breast milk in low concentrations; estimated relative infant dose is 2.4% of maternal weight-adjusted dose. M/P ratio is not well established. Caution is advised, monitor for infant sedation and respiratory depression.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
Pregnancy may alter buprenorphine pharmacokinetics; dose adjustments may be needed to avoid withdrawal or oversedation. Monitor clinical response and adjust doses in increments of 2-4 mg sublingual buprenorphine as needed, guided by withdrawal symptoms and cravings.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
BUNAVAIL (buprenorphine/naloxone) sublingual film is indicated for maintenance treatment of opioid dependence. Administer as a single daily dose; films can be cut to achieve lower doses. Avoid abrupt discontinuation to prevent withdrawal. Monitor for respiratory depression, especially during induction. Use with caution in patients with hepatic impairment; naloxone component may precipitate withdrawal in opioid-tolerant patients if injected.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Place the film under the tongue and allow it to dissolve completely; do not chew, swallow, or move the film after placement.,Do not drink or eat until the film has completely dissolved.,Avoid use of alcohol or other central nervous system depressants (e.g., benzodiazepines) while taking this medication as it may increase risk of respiratory depression.,Do not stop taking this medication suddenly without consulting your healthcare provider as withdrawal symptoms may occur.,Store at room temperature away from moisture and heat; keep out of reach of children.,This medication can cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Inform all healthcare providers that you are taking this medication before any surgery or emergency treatment.,Do not take other opioids, including illicit drugs, while on this medication as it may cause severe withdrawal or overdose.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUNAVAIL vs CARISOPRODOL COMPOUND, answered by our medical review team.
BUNAVAIL is a Opioid Partial Agonist Combination that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUNAVAIL and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUNAVAIL is: For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUNAVAIL and CARISOPRODOL COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUNAVAIL is classified as Category C. Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.